临床18F-FDG与淀粉样蛋白脑正电子发射断层/CT在认知障碍检查中的应用:现况如何
本文综述18F-FDG PET/CT与淀粉样蛋白PET/CT在认知障碍检查中的作用,概述两者适应证、作用机制、技术、患者准备与采集参数,并提供常见认知障碍的判读框架及避免判读陷阱的提示。
要点
- 18F-FDG PET/CT反映脑葡萄糖代谢,用于认知障碍的检查。
- 淀粉样蛋白PET/CT可能从根本上改变阿尔茨海默病的管理。
- 综述提供常见认知障碍的判读框架及避免判读陷阱的提示。
核心结论
- 18F-FDG PET/CT有助于认知障碍的检查,淀粉样蛋白PET/CT的出现可能从根本上改变最常见痴呆类型阿尔茨海默病的管理。
研究设计与样本
- 综述,旨在帮助读者理解18F-FDG PET/CT在认知障碍检查中的作用及淀粉样蛋白PET/CT的影响。
临床应用与阅片要点
- 综述概述了18F-FDG PET/CT与淀粉样蛋白PET/CT在认知障碍中的适应证。
- 综述详述了两者的作用机制、技术、患者准备与采集参数。
- 综述提供了常见认知障碍的判读框架及避免判读陷阱的提示。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The number of people living with dementia is increasing, but as yet there remains no cure or disease-modifying treatment. This review aims to help readers understand the role of 18F-FDG PET/CT imaging in the investigation of cognitive impairment and how the advent of amyloid PET/CT imaging may hold the key to radically changing management of the most common form of dementia - Alzheimer's disease. The indications for 18F-FDG PET/CT and amyloid PET/CT imaging in cognitive impairment are outlined. Additionally, the mechanisms of action, technique, patient preparation and acquisition parameters for both are detailed. We conclude by providing a framework for interpreting 18F-FDG PET/CT and amyloid PET/CT imaging in the more common conditions that lead to cognitive impairment conditions with tips on avoiding pitfalls in interpretation.
引用
- Dumba M, Khan S, Patel N, et al. Clinical 18F-FDG and amyloid brain positron emission tomography/CT in the investigation of cognitive impairment: where are we now? Br J Radiol. 2019. PMID: 30982329. doi:10.1259/bjr.20181027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。